

Roger J BrÃ¼ggemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041406/publications.pdf>

Version: 2024-02-01

171
papers

8,471
citations

53660

45
h-index

54797

84
g-index

175
all docs

175
docs citations

175
times ranked

8784
citing authors

#	ARTICLE	IF	CITATIONS
1	Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 564-569.	1.0	3
2	Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. <i>Archives of Disease in Childhood</i> , 2022, 107, 400-406.	1.0	1
3	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology</i> , 2022, 9, e58-e72.	2.2	29
4	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1003-1009.	2.8	8
5	Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 869-879.	1.6	4
6	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	13.6	311
7	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 907-918.	1.6	10
8	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1725-1732.	1.3	1
9	Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 699-703.	1.3	3
10	Precision Therapy for Invasive Fungal Diseases. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 18.	1.5	4
11	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study. <i>Mycoses</i> , 2022, 65, 656-660.	1.8	3
12	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2217-2226.	1.3	4
13	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , 2022, 9, e361-e373.	2.2	25
14	Risk-proportionate approach to paediatric clinical trials: The legal requirements, challenges, and the way forward under the European Union Clinical Trials Regulation. <i>Clinical Trials</i> , 2022, , 174077452210938.	0.7	1
15	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1167-1175.	1.6	9
16	The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. <i>Clinical Infectious Diseases</i> , 2021, 73, e3615-e3616.	2.9	9
17	Acute Endophthalmitis after Cataract Surgery: Clinical Characteristics and the Role of Intracameral Antibiotic Prophylaxis. <i>Ophthalmology Retina</i> , 2021, 5, 503-510.	1.2	8
18	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , 2021, 21, e149-e162.	4.6	586

#	ARTICLE	IF	CITATIONS
19	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 727-733.	0.8	2
20	More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine. <i>International Journal of Infectious Diseases</i> , 2021, 103, 402-403.	1.5	2
21	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. <i>Journal of Infectious Diseases</i> , 2021, 223, 1322-1333.	1.9	61
22	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1â€“18 Years. <i>AAPS Journal</i> , 2021, 23, 53.	2.2	12
23	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. <i>Cell Reports Medicine</i> , 2021, 2, 100289.	3.3	15
24	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. <i>Mycoses</i> , 2021, 64, 1111-1116.	1.8	3
25	Clinical Pharmacokinetics of Triazoles in Pediatric Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1103-1147.	1.6	12
26	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
27	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1361-1372.	1.6	9
28	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
29	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. <i>Lancet Respiratory Medicine</i> , 2021, 9, 795-802.	5.2	56
30	High unbound flucloxacillin fraction in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3220-3228.	1.3	9
31	Invasive pulmonary aspergillosis associated with viral pneumonitis. <i>Current Opinion in Microbiology</i> , 2021, 62, 21-27.	2.3	39
32	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0122921.	1.8	50
33	Oral Antibiotics in Patients with Short Bowel Syndrome: Do or Donâ€™t?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 821-823.	0.6	3
34	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. <i>Antibiotics</i> , 2021, 10, 1112.	1.5	5
35	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1234-1241.	1.3	14
36	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. <i>Microorganisms</i> , 2021, 9, 2068.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Multinational Observational Cohort Study of COVID-19-associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , 2021, 27, 2892-2898.	2.0	82
38	Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 909.	1.5	29
39	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 961-966.	1.3	2
40	Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?" <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	0
41	Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	4
42	1162. Antifungal Use in Immunocompromised Children in Europe: a 12-week Multicenter Modified Point prevalence Study (CALYPSO). <i>Open Forum Infectious Diseases</i> , 2021, 8, S672-S673.	0.4	1
43	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 349-350.	2.9	20
44	Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature. <i>Clinical Pharmacokinetics</i> , 2020, 59, 173-205.	1.6	61
45	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. <i>Clinical Infectious Diseases</i> , 2020, 70, 2213-2215.	2.9	16
46	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. <i>Clinical Pharmacokinetics</i> , 2020, 59, 591-603.	1.6	14
47	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 303-317.	1.1	37
48	High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. <i>Mycoses</i> , 2020, 63, 122-130.	1.8	35
49	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 274.	1.5	7
50	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
51	Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	22
52	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3286-3292.	1.3	9
53	Author's Reply to Liu et al.: "Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab" <i>Clinical Pharmacokinetics</i> , 2020, 59, 1645-1646.	1.6	0
54	Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2497-2506.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe</i> , The, 2020, 1, e53-e55.	3.4	158
56	Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2666-2669.	1.3	2
57	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
58	In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant <i>Aspergillus fumigatus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2582-2586.	1.3	5
59	Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 997.	3.8	0
60	Implications for IV posaconazole dosing in the era of obesity. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1006-1013.	1.3	18
61	Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> , 2020, 80, 671-695.	4.9	80
62	Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 770-774.	2.3	10
63	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. <i>Medical Mycology</i> , 2020, 58, 874-880.	0.3	8
64	Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. <i>ELife</i> , 2020, 9, .	2.8	235
65	Antifungal drugs: What brings the future?. <i>Medical Mycology</i> , 2019, 57, S328-S343.	0.3	141
66	Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 790-797.	1.1	24
67	ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1096-1113.	2.8	112
68	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 112.	1.7	13
69	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 161-167.	1.4	9
70	A stitch in time saves nine. <i>Lancet</i> , The, 2019, 393, 1936.	6.3	0
71	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S244-S259.	2.9	40
72	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S260-S274.	2.9	73

#	ARTICLE	IF	CITATIONS
73	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1333-1343.	1.6	11
74	Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0213913.	1.1	20
75	The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1656-1661.	1.3	18
76	Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. <i>Medical Mycology</i> , 2019, 57, 937-943.	0.3	16
77	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. <i>Clinical Pharmacokinetics</i> , 2019, 58, 859-874.	1.6	82
78	Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 829-830.	1.3	0
79	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 978-985.	1.3	23
80	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. <i>Pediatric Nephrology</i> , 2019, 34, 507-515.	0.9	13
81	Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 680.	3.8	206
82	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 275-285.	1.5	135
83	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 465-471.	0.8	20
84	Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	28
85	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole resistance. A nationwide survey and rationale for the <sc>DB</sc>-MSG 002 study protocol. <i>Mycoses</i> , 2018, 61, 656-664.	1.8	26
86	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. <i>Clinical Microbiology and Infection</i> , 2018, 24, e1-e38.	2.8	942
87	Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1471.	3.3	70
88	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 475-489.	1.6	48
89	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 134-142.	1.3	29
90	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	1.7	125

#	ARTICLE	IF	CITATIONS
91	Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 106-113.	1.4	23
92	Amphotericin B and terbinafine but not the azoles prolong survival in <i>Galleria mellonella</i> larvae infected with <i>Madurella mycetomatis</i> . <i>Medical Mycology</i> , 2018, 56, 469-478.	0.3	22
93	Antifungal PK/PD in the Critically Ill. , 2018, , 213-238.		1
94	Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. <i>Clinical Pharmacokinetics</i> , 2018, 57, 267-286.	1.6	55
95	Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1980-1988.	1.1	36
96	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	1.3	186
97	Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1089, 16-23.	1.2	10
98	Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3095-3101.	1.3	13
99	Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2493-2496.	1.3	14
100	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). <i>European Journal of Human Genetics</i> , 2018, 26, 1417-1423.	1.4	20
101	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1197-1206.	1.6	27
102	Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring. <i>European Neuropsychopharmacology</i> , 2017, 27, 205-216.	0.3	27
103	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. <i>Intensive Care Medicine</i> , 2017, 43, 1021-1032.	3.9	100
104	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.	1.6	32
105	Itraconazole or Amphotericin B for Talaromycosis. <i>New England Journal of Medicine</i> , 2017, 377, 1402-1403.	13.9	4
106	Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	33
107	Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. <i>Transplant Infectious Disease</i> , 2017, 19, e12751.	0.7	89
108	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17

#	ARTICLE	IF	CITATIONS
109	Early postnatal gentamicin and ceftazidime treatment in normal and food restricted neonatal wistar rats: Implications for kidney development. <i>Birth Defects Research</i> , 2017, 109, 1228-1235.	0.8	1
110	Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 412-421.	1.0	38
111	<i>CYP2C19</i> Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 235-246.	1.0	29
112	Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	29
113	Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. <i>Pediatric Transplantation</i> , 2016, 20, 492-499.	0.5	14
114	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. <i>Immunobiology</i> , 2016, 221, 1141.	0.8	1
115	A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1366-1372.	1.2	3
116	The role of the multidisciplinary team in antifungal stewardship. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii37-ii42.	1.3	35
117	Drug-Drug Interactions in Treatment Using Azole Antifungal Agents. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2622.	3.8	0
118	Does Weight Impact Anidulafungin Pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1289-1294.	1.6	18
119	Antifungal therapy: drug-drug interactions at your fingertips” authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2062.2-2063.	1.3	1
120	Antifungal therapy: drug-drug interactions at your fingertips. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 285-289.	1.3	14
121	Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3372-3379.	1.4	80
122	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. <i>Clinical Pharmacokinetics</i> , 2016, 55, 723-733.	1.6	35
123	Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children. <i>PLoS ONE</i> , 2016, 11, e0167433.	1.1	66
124	Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis. , 2016, , .		0
125	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1166-1174.	1.3	22
126	Fundament and Prerequisites for the Application of an Antifungal TDM Service. <i>Current Fungal Infection Reports</i> , 2015, 9, 122-129.	0.9	25

#	ARTICLE	IF	CITATIONS
127	Impact of special patient populations on the pharmacokinetics of echinocandins. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 799-815.	2.0	36
128	Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. <i>Current Opinion in Pharmacology</i> , 2015, 24, 38-44.	1.7	60
129	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4403-4409.	1.4	48
130	Pharmacodynamics of Isavuconazole in an <i>Aspergillus fumigatus</i> Mouse Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2855-2866.	1.4	60
131	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	6.5	262
132	Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2964-2967.	1.4	13
133	Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6879-6885.	1.4	65
134	Pharmacokinetics of caspofungin in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3294-3299.	1.3	61
135	The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. <i>Drug Resistance Updates</i> , 2014, 17, 37-50.	6.5	89
136	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2988-2994.	1.3	29
137	Screening of the central nervous system in children with invasive pulmonary aspergillosis. <i>Medical Mycology Case Reports</i> , 2014, 4, 8-11.	0.7	14
138	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. <i>Blood</i> , 2014, 124, 3027-3029.	0.6	12
139	Poor Performance of Laboratories Assaying Newly Developed Antiretroviral Agents. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 824-827.	1.0	4
140	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 931-941.	2.0	65
141	Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2013, 14, 400.	0.7	18
142	Insufficient serum caspofungin levels in a paediatric patient on ECMO. <i>Medical Mycology Case Reports</i> , 2013, 2, 23-24.	0.7	17
143	Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 977-981.	1.3	41
144	Pharmacokinetic Profile of Voriconazole in a Critically Ill Patient on Therapeutic Plasma Exchange. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 141-143.	1.0	11

#	ARTICLE	IF	CITATIONS
145	Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1888-1894.	1.4	40
146	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 385-393.	1.3	60
147	Favorable Outcome of Neonatal Cerebrospinal Fluid Shunt-Associated Candida Meningitis with Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2391-2393.	1.4	12
148	Pharmacodynamics of Anidulafungin against Clinical <i>Aspergillus fumigatus</i> Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 303-308.	1.4	16
149	Posaconazole Treatment in Hematology Patients. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 320-325.	1.0	19
150	Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 887-888, 79-84.	1.2	41
151	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. <i>Transplant Infectious Disease</i> , 2012, 14, 440-443.	0.7	14
152	A rare case of supraspinatus tendon rupture. <i>Annals of Hematology</i> , 2012, 91, 131-132.	0.8	4
153	A Twice Daily Posaconazole Dosing Algorithm for Children With Chronic Granulomatous Disease. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 794-797.	1.1	42
154	Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 533-534.	1.1	42
155	Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to <i>Aspergillus fumigatus</i> with Attenuated Susceptibility to Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3564-3566.	1.4	35
156	Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1853-1856.	1.3	56
157	<i>Rhizopus Oryzae</i> Skin Infection Treated With Posaconazole in a Boy With Chronic Granulomatous Disease. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 578.	1.1	14
158	Paracetamol for intravenous use in medium- and intensive care patients: pharmacokinetics and tolerance. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 713-719.	0.8	57
159	Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2188-2194.	1.3	17
160	Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 107-113.	1.3	36
161	Oseltamivir Dosing in Children Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 2010, 50, 1427-1428.	2.9	11
162	Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4758-4764.	1.4	80

#	ARTICLE	IF	CITATIONS
163	Efficacy of Posaconazole against Three Clinical <i>Aspergillus fumigatus</i> Isolates with Mutations in the <i>cyp51A</i> Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 860-865.	1.4	110
164	Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. <i>Clinical Infectious Diseases</i> , 2009, 48, 1441-1458.	2.9	368
165	International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 303-305.	1.4	56
166	Pharmacokinetic drug interactions of azoles. <i>Current Fungal Infection Reports</i> , 2008, 2, 20-27.	0.9	13
167	Single-Dose Fluconazole versus Standard 2-Week Therapy for Oropharyngeal Candidiasis in HIV-Infected Patients: A Randomized, Double-Blind, Double-Dummy Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1270-1276.	2.9	37
168	Therapeutic Drug Monitoring of Voriconazole. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 403-411.	1.0	116
169	Therapeutic Drug Monitoring of Voriconazole in a Child With Invasive Aspergillosis Requiring Extracorporeal Membrane Oxygenation. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 643-646.	1.0	43
170	Mechanism of Oxime Reactivation of Acetylcholinesterase Analyzed by Chirality and Mutagenesis. <i>Biochemistry</i> , 2000, 39, 5750-5757.	1.2	116
171	Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. <i>Chemico-Biological Interactions</i> , 1999, 119-120, 3-15.	1.7	21